-

XiFin Named to Inc. 5000 List of Fastest-Growing Private Companies in America for 13th Time

Ongoing Innovation and Industry Leadership in Artificial Intelligence-Driven Health IT Solutions Helps Fuel 157% Revenue Growth Over Three Years

SAN DIEGO--(BUSINESS WIRE)--XiFin, a leading provider of innovative healthcare information technologies and services that deliver AI-enabled operational efficiency, interoperability, and simplicity, announced today that it has been named to Inc. 5000, Inc. Magazine’s annual ranking of the 5,000 fastest-growing private companies in America for a thirteenth time – a feat only 25 companies have accomplished since the award’s inception. The Inc. 5000 award is recognition of XiFin’s industry leadership in revenue cycle management (RCM) and workflow automation and of the company’s revenue growth of 157% over three years.

“Out of the tens of thousands of companies that have been recognized by Inc. across its five decades of tracking fast growth, some have disappeared, others, like Microsoft, Zillow, and Meta, have become household names, but very few have proven the consistent year-after-year growth to be an Inc. 5000 honoree a handful of times,” says Inc. editor-in-chief Scott Omelianuk. “To do it 13 times is a remarkable feat of operational savvy, team building, and consumer connection nearly unheard of in the fast-changing landscape of today’s business.”

Healthcare providers and facilities in the United States spent $17.9 billion on cloud-based technologies in 2022, with XiFin’s SaaS-based solutions addressing $8.3 billion of that total. XiFin’s client base includes 75% of the largest public laboratories and four of the five top integrated delivery networks. OmniSYS, XiFin Pharmacy Solutions, supports more than 30,000 retail pharmacies, including all five of the largest national retail pharmacy chains in the United States

“Innovation has been key to our growth, from investing early in AI technology to pioneering solutions that address the convergence of pharmacy and diagnostics,” said Lâle White, executive chair and CEO at XiFin. “Ultimately, our growth is a reflection of our ability to empower healthcare organizations to achieve greater efficiency so they can concentrate on doing good for patients and for the healthcare delivery system as a whole.”

In addition to being named to the Inc. 5000 list, XiFin has been recognized recently by Energage in earning two Top Workplaces USA awards for prioritizing a people-centered culture and giving employees a voice, and for the company’s investment in their employees’ wellbeing, satisfaction, and fulfillment while leading in the healthcare industry. XiFin also was recognized this year by Black Book Research for receiving the top customer and user satisfaction scores in nine of 18 revenue cycle management services key performance indicators and ranking #1 overall in the Black Book Market Research survey of healthcare and medical users of RCM solutions for laboratories, radiology, and outpatient service providers and other ancillaries.

Methodology

Companies on the 2023 Inc. 5000 are ranked according to percentage revenue growth from 2019 to 2022. To qualify, companies must have been founded and generating revenue by March 31, 2019. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2022.

About XiFin

XiFin is a healthcare information technology company that empowers healthcare organizations to navigate an increasingly complex and evolving healthcare landscape. Through innovative technologies and services, we deliver AI-enabled operational efficiency, interoperability, and simplicity. Our solutions enable organizations to achieve stronger finances, streamline operations, and develop industry-leading business strategies. XiFin solutions deliver THE POWER TO DO GOODTM so that healthcare organizations can do more good for more patients. Visit www.XiFin.com, follow XiFin on Twitter and LinkedIn, or subscribe to the XiFin blog to learn more.

Contacts

Fran Ducharme
fducharme@xifin.com
(858) 436-2939

XiFin

Details
Headquarters: San Diego, CA
CEO: Lâle White
Employees: 900+
Organization: PRI

Release Versions

Contacts

Fran Ducharme
fducharme@xifin.com
(858) 436-2939

Social Media Profiles
More News From XiFin

XiFin Announces Empower AI RCM Ecosystem to Redefine How Healthcare Revenue Operations Scale

SAN DIEGO--(BUSINESS WIRE)--XiFin, Inc., a leader in revenue cycle management (RCM) solutions, today announced XiFin® Empower AI, an interoperable, intelligent AI RCM ecosystem designed to coordinate AI, automation, and agentic workflows across healthcare revenue operations. Built on XiFin’s industry-trusted encounter, financial, and payor data, XiFin Empower AI can deliver measurable improvements across the revenue cycle—including accelerated payment velocity, fewer manual touches, higher firs...

XiFin Reports Double-Digit Segment Growth and 21.1% Increase in Empower RCM Volume; Names New CTO to Accelerate AI Strategy

SAN DIEGO--(BUSINESS WIRE)--XiFin, Inc., a leader in AI-enabled revenue cycle management (RCM), today reported strong operational growth across key segments in 2025, including 16.4% growth in its molecular diagnostics segment and 13.3% growth in its hospital segment. Volume flowing through XiFin® Empower RCM increased 21.1%, reflecting accelerating adoption of the company’s next-generation AI-powered revenue cycle solution. Building on this momentum, XiFin also announced the appointment of Sanj...

XiFin Builds on Empower CareALERTS Success with New Capabilities for Pharmacy

SAN DIEGO--(BUSINESS WIRE)--XiFin, Inc., a leader in revenue cycle management (RCM), including billing solutions enhanced with artificial intelligence (AI), today announced the expansion of its proven CareALERTS™ smart clinical messaging technology, with a pharmacy-focused offering that alerts pharmacists to patient-specific vaccination opportunities directly within their existing workflows. By delivering real-time immunization alerts at the point of care, CareALERTS for Pharmacy enables pharma...
Back to Newsroom